The developer of a drug for the rare multiple system atrophy, Alterity will launch a pivotal phase III trial after a go-ahead ...
Although mortality is increased in patients with Parkinson's disease compared with the general population, this does not appear to be the case for patients who present with normal cognitive function, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results